Ribo and Insilico Medicine Partner to Advance AI Guided siRNA Drug Development

May 12, 2026
Suzhou Ribo Life Science and Insilico Medicine have announced a strategic collaboration to accelerate siRNA drug development using AI platforms, combining Ribo's RNAi expertise with Insilico's Pharma.AI technology.

Suzhou Ribo Life Science has entered a strategic collaboration with Insilico Medicine to accelerate siRNA drug development through the use of AI, announced in a press release. The partnership combines Ribo's experience in RNA interference drug research with Insilico's AI based drug discovery platforms.

The two companies will work together on target discovery, drug molecule design, optimization, and AI assisted clinical translation. Ribo has integrated AI into its siRNA drug development system, including an algorithm driven sequence design platform and a ligand screening platform that enables rapid identification and optimization of candidate molecules.

Insilico will contribute its Pharma.AI platform, which has recently been upgraded to support multiple scenarios in oligonucleotide drug development. The collaboration expands on previous joint work between the companies in intelligent autonomous high throughput screening.

Through this agreement, both companies aim to improve the efficiency and success rate of siRNA drug development and bring new therapies addressing unmet clinical needs to patients worldwide.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Enterprise AI Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Enterprise AI Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Enterprise

05/12
Coupa Acquires Rossum to Expand AI Document Processing Across Spend Management Platform
05/12
Saturn Cloud and Mirantis Partner on Full Stack AI Platform for NeoClouds and Enterprises
05/12
CGI Expands IT Partnership with Stockmann to Advance Digital Development
05/12
AccountTECH Invests in Private AI Infrastructure for Accounting Applications
05/12
Bounteous Acquires Cartesian to Strengthen Data and AI Capabilities

More from: Life Sciences

05/12
IPC Global Named Technology Partner for American Medical Association Precision Education Grant
05/12
Labcorp Expands Diagnostic Integration with Epic's Aura Platform
05/12
Renalytix and Carna Health Partner on AI Kidney Disease Management
05/12
Hyro Report Shows Deep EHR Integrations Drive Higher ROI for Healthcare AI Agents
05/12
Susan Wojcicki Foundation Launches to Advance Early Detection of Lung Cancer

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like